Hand Dermatitis

March 7, 2016

Santalis Pharmaceuticals has released results of Santalia AD product regimen in a single-center, open-label study enrolling 25 patients, ages 3 months to 12 years with mild, moderate or severe atopic dermatitis with a mean beginning Eczema Area and Severity Index (EASI) score of 11.1 (moderate). Treatable atopic dermatitis, for this study, was defined as an EASI score ≥5 but ≤52. The EASI scoring system is a validated investigator-assessed instrument, which measures the severity of clinical attributes of atopic dermatitis in patients. Patients (or their caregivers) were instructed to apply the Santalia AD Regimen cleanser and cream twice daily for 60 days and bubble bath at least three times weekly. 22 out of 25 patients completed the study. 82% (18/22) of patients met the primary efficacy endpoint (a 25% reduction in their EASI score). 91% (20/22) of patients experienced a reduction in their EASI score. 68% of patients achieved an IGA score of “much improved” or “very much improved” with a minimum two-grade improvement after eight weeks of treatment. 61.9% of patients achieved an IGA score of “much improved” or “very much improved” with a minimum two-grade improvement after four weeks of treatment. Patients demonstrated an average 60% reduction in EASI score over baseline. In patient diary responses, the aggregate score for all diary responses went from zero at study commencement to 3.1 (much improvement) in eight weeks. 74.7% of respondents reported an aggregate score of three (much improvement) or four (very much improved) at study end. 78.9% reported a reduction in both redness and an improvement in skin texture of the treated area and 73.7% reported an improvement in pain or irritation of the treatment area. 

July 20, 2015

Anacor Pharmaceuticals reported results of two phase III studies of Crisaborole Topical Ointment, 2% (formerly AN2728) in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The studies were multicenter, double-blind, vehicle-controlled studies of over 750 patients each, aged 2 years and older with mild-to-moderate atopic dermatitis (defined as an Investigator’s Static Global Assessment (ISGA) score of two (mild) or three (moderate)). The ISGA is a five-point scale ranging from zero (clear) to four (severe). Patients were randomized in a 2:1 ratio (crisaborole:vehicle). Crisaborole or vehicle was applied twice daily for 28 days. Time to Success in ISGA: Time course to success in ISGA between crisaborole and vehicle was statistically significantly different (p<0.001) in each study, with patients treated with crisaborole achieving success earlier than vehicle-treated patients. Percent of patients who achieved success in the ISGA: study AD-301, (crisaborole/vehicle), N=503/256, 32.8%/25.4% (p=0.038); study AD-302, (crisaborole/vehicle), N=513/250 31.4%/18% (p<0.001). In addition to the phase III pivotal studies, the company is conducting an open-label long-term safety study to evaluate the safety of intermittent use of crisaborole for up to 12 months.

Related Medical Areas